Dr. Anne AltmeyerFormer CEO, TigaTx; Board Member, Corbus
Dr. Anne Altmeyer is an accomplished biotech executive and board member with over two decades of leadership in the biopharmaceutical industry.
From 2021 until its acquisition by Epsilogen, Ltd. in 2025, she served as President, CEO, and Director of TigaTx, a company developing engineered IgA monoclonal antibodies for cancer and other diseases.
Previously, she was Chief Business Officer at Sigilon Therapeutics (acquired by Eli Lilly) and Adicet Bio (Nasdaq: ACET), Vice President of Business Development & Licensing at Baxalta (acquired by Shire), and held senior roles in Business Development and Project Leadership at Novartis Pharmaceuticals.
She began her industry career in project management at Merck & Co., Inc. (NYSE: MRK). Since 2022, Dr. Altmeyer has served on the Board of Directors of Corbus Pharmaceuticals (NASDAQ: CRBP).
She holds a Ph.D. in Immunology from Strasbourg University, France; an M.B.A. from Rutgers University; and an M.P.H. from the University of Medicine and Dentistry of New Jersey; and completed postdoctoral training at NYU School of Medicine and Cornell University Medical College in New York City.
